Trial · NCT02845336
Celecoxib for Thyroid Eye Disease
NCT02845336, Phase 2, Terminated, Johns Hopkins University; results first posted 2020-07-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Celecoxib for Thyroid Eye Disease. Trials, record NCT02845336. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02845336
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Celecoxib for Thyroid Eye Disease
- NCT number
- NCT02845336
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Thyroid Eye Disease
- Interventions
- Celecoxib, artificial tears
- First posted
- 2016-07-27
- Last updated
- 2020-07-31
- Results first posted
- 2020-07-31
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Thyroid Eye Disease Clinical Activity Score | At baseline, 1, 3 and 6 months | A clinical score based on examination findings at each clinic visit. Clinical Activity Scores ranged from 0 to 10; 0 = Normal 1-3 = Mild 4-6 = Moderate 7-10 = Severe |
| Secondary | Proptosis as Measured in Millimeters With an Exophthalmometer (Right Eye) | At baseline, 1, 3 and 6 months | A clinical measure of how prominent the eyes are and any change in this measure over the duration of the study, as measured in millimeters with an exophthalmometer. |
| Secondary | Proptosis as Measured in Millimeters With an Exophthalmometer (Left Eye) | At baseline, 1, 3 and 6 months | A clinical measure of how prominent the eyes are and any change in this measure over the duration of the study, as measured in millimeters with an exophthalmometer. |
| Secondary | Number of Participants With Ocular Misalignment | At baseline | Presence or absence of ocular misalignment measured in prism diopters. |
| Secondary | Number of Participants With Ocular Misalignment | At 1 month | Presence or absence of ocular misalignment measured in prism diopters. |
| Secondary | Number of Participants With Ocular Misalignment | At 3 months | Presence or absence of ocular misalignment measured in prism diopters. |
| Secondary | Number of Participants With Ocular Misalignment | At 6 months | Presence or absence of ocular misalignment measured in prism diopters. |
| Secondary | Eyelid Retraction as Measured in Millimeters (Right Eye) | At baseline, 1, 3 and 6 months | A clinical measure of the most common manifestation of thyroid eye disease--change in eyelid retraction as measured in millimeters at each visit over the duration of the study. |
| Secondary | Eyelid Retraction as Measured in Millimeters (Left Eye) | At baseline, 1, 3 and 6 months | A clinical measure of the most common manifestation of thyroid eye disease--change in eyelid retraction as measured in millimeters at each visit over the duration of the study. |
| Secondary | Quality of Life as Assessed by a Thyroid Eye Disease Specific Survey of Quality of Life | 6 months | Thyroid eye disease specific survey of quality of life will be administered, and change in quality of life score over the duration of the study will be measured. |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Thyroid Eye Disease Clinical Activity Score | At baseline, 1, 3 and 6 months | No participant in control arm was assessed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proptosis as Measured in Millimeters With an Exophthalmometer (Right Eye) | At baseline, 1, 3 and 6 months | No participant in control arm was assessed for this outcome measure. | millimeters | NUMBER |
| SECONDARY | Proptosis as Measured in Millimeters With an Exophthalmometer (Left Eye) | At baseline, 1, 3 and 6 months | No participant in control arm was assessed for this outcome measure. | millimeters | NUMBER |
| SECONDARY | Number of Participants With Ocular Misalignment | At baseline | No participant in control arm was assessed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Ocular Misalignment | At 1 month | No participant in control arm was assessed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Ocular Misalignment | At 3 months | No participant in control arm was assessed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Ocular Misalignment | At 6 months | No participant in control arm was assessed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Eyelid Retraction as Measured in Millimeters (Right Eye) | At baseline, 1, 3 and 6 months | No participant in control arm was assessed for this outcome measure. | millimeters | NUMBER |
| SECONDARY | Eyelid Retraction as Measured in Millimeters (Left Eye) | At baseline, 1, 3 and 6 months | No participant in control arm was assessed for this outcome measure. | millimeters | NUMBER |
| SECONDARY | Quality of Life as Assessed by a Thyroid Eye Disease Specific Survey of Quality of Life | 6 months | This measure was not assessed. No data was collected. |
Source ClinicalTrials.gov
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | Baseline / Normal | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | Baseline / Mild | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | Baseline / Moderate | 1 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | Baseline / Severe | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 1 month / Normal | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 1 month / Mild | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 1 month / Moderate | 1 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 1 month / Severe | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 3 months / Normal | 0 | Participants | |
| Thyroid Eye Disease Clinical Activity Score | Celecoxib | 3 months / Mild | 0 | Participants |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Celecoxib | 6 | |
| Overall Study | STARTED | Control | 1 | |
| Overall Study | COMPLETED | Celecoxib | 1 | |
| Overall Study | COMPLETED | Control | 0 | |
| Overall Study | NOT COMPLETED | Celecoxib | 5 | |
| Overall Study | NOT COMPLETED | Control | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Celecoxib | 0 | 1 |
| Total, all-cause mortality | Control | 0 | 0 |
| Total, other adverse events | Celecoxib | 0 | 1 |
| Total, other adverse events | Control | 0 | 0 |
| Total, serious adverse events | Celecoxib | 0 | 1 |
| Total, serious adverse events | Control | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02845336
GET https://conductscience.org/api/trials/v1/NCT02845336/results?page=2